Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in fully vaccinated recipients.

Matéria original

Anterior

Human genetic and immunological determinants of critical COVID-19 pneumonia

Próxima

The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment